Awakening dormant haematopoietic stem cells
Haematopoietic stem cells (HSCs) in mouse bone marrow are located in specialized niches
as single cells. During homeostasis, signals from this environment keep some HSCs …
as single cells. During homeostasis, signals from this environment keep some HSCs …
Engineering in medicine to address the challenge of cancer drug resistance: from micro-and nanotechnologies to computational and mathematical modeling
Drug resistance has profoundly limited the success of cancer treatment, driving relapse,
metastasis, and mortality. Nearly all anticancer drugs and even novel immunotherapies …
metastasis, and mortality. Nearly all anticancer drugs and even novel immunotherapies …
Inferring the dynamics of mutated hematopoietic stem and progenitor cells induced by IFNα in myeloproliferative neoplasms
M Mosca, G Hermange, A Tisserand… - Blood, The Journal …, 2021 - ashpublications.org
Classical BCR-ABL–negative myeloproliferative neoplasms (MPNs) are clonal disorders of
hematopoietic stem cells (HSCs) caused mainly by recurrent mutations in genes encoding …
hematopoietic stem cells (HSCs) caused mainly by recurrent mutations in genes encoding …
To wake up cancer stem cells, or to let them sleep, that is the question
S Takeishi, KI Nakayama - Cancer science, 2016 - Wiley Online Library
Cancer stem cells (CSC s) generate transient‐amplifying cells and thereby contribute to
cancer propagation. A fuller understanding of the biological features of CSC s is expected to …
cancer propagation. A fuller understanding of the biological features of CSC s is expected to …
[HTML][HTML] Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy
JC Chomel, AG Turhan - Oncotarget, 2011 - ncbi.nlm.nih.gov
Targeted therapies of chronic myeloid leukemia (CML) using tyrosine kinase inhibitors (TKI)
have profoundly changed the natural history of the disease with a major impact on survival …
have profoundly changed the natural history of the disease with a major impact on survival …
Blood cell dynamics: half of a century of modelling
L Pujo-Menjouet - Mathematical Modelling of Natural …, 2016 - mmnp-journal.org
The objective of this paper is to give a review of the main works dealing with mathematical
modeling of blood cell formation, disorders and treatments within the past fifty years. From …
modeling of blood cell formation, disorders and treatments within the past fifty years. From …
Model-based decision rules reduce the risk of molecular relapse after cessation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia
M Horn, I Glauche, MC Müller… - Blood, The Journal …, 2013 - ashpublications.org
Molecular response to imatinib (IM) in chronic myeloid leukemia (CML) is associated with a
biphasic but heterogeneous decline of BCR-ABL transcript levels. We analyzed this …
biphasic but heterogeneous decline of BCR-ABL transcript levels. We analyzed this …
The ecology in the hematopoietic stem cell niche determines the clinical outcome in chronic myeloid leukemia
Chronic myeloid leukemia (CML) is a blood disease that disrupts normal function of the
hematopoietic system. Despite the great progress made in terms of molecular therapies for …
hematopoietic system. Despite the great progress made in terms of molecular therapies for …
A simple mathematical model based on the cancer stem cell hypothesis suggests kinetic commonalities in solid tumor growth
R Molina-Peña, MM Álvarez - PloS one, 2012 - journals.plos.org
Background The Cancer Stem Cell (CSC) hypothesis has gained credibility within the
cancer research community. According to this hypothesis, a small subpopulation of cells …
cancer research community. According to this hypothesis, a small subpopulation of cells …
Fitness conferred by BCR-ABL kinase domain mutations determines the risk of pre-existing resistance in chronic myeloid leukemia
Chronic myeloid leukemia (CML) is the first human malignancy to be successfully treated
with a small molecule inhibitor, imatinib, targeting a mutant oncoprotein (BCR-ABL). Despite …
with a small molecule inhibitor, imatinib, targeting a mutant oncoprotein (BCR-ABL). Despite …